1i. Eliminating trypanosome carriage in Ugandan cattle prevents sleeping sickness in humans, stimulating the formation of “Stamp Out Sleeping Sickness (SoS)” a Public Private Partnership that is eliminating the disease from Uganda
Submitting Institutions
University of Edinburgh,
SRUCUnit of Assessment
Agriculture, Veterinary and Food ScienceSummary Impact Type
EnvironmentalResearch Subject Area(s)
Agricultural and Veterinary Sciences: Animal Production, Veterinary Sciences
Medical and Health Sciences: Medical Microbiology
Summary of the impact
Impact: Economics, policy, animal and human health: In 2006, SoS
(a Public Private Partnership-PPP) was established involving: University
of Edinburgh, a pharmaceutical company, a charity, and the Govt. of Uganda
to control sleeping sickness by eliminating Trypanasome carriage in
cattle. The prevalence of trypanosomiasis has been reduced by 75% and
sleeping sickness cases have fallen year on year since the PPP was
established and Uganda has received a cost benefit between US$125 and
$400M
Beneficiaries: The Ugandan population, Ugandan Cattle population.
Significance: Sleeping sickness, which is difficult to diagnose
and treat in humans, is often fatal. Ten million Ugandans are at risk from
sleeping sickness. SoS established a veterinary network in Uganda
producing
Attribution: Professor Welburn (University of Edinburgh, UoE)
founded SoS and developed essential diagnostic techniques.
Reach: SoS provides a model for the elimination of the disease
across sub Saharan Africa in an economically sustainable fashion - with
over 22 million people at risk.
Underpinning research
Sleeping sickness is a disease transmitted by tsetse flies in sub-Saharan
Africa; it is expensive and difficult to diagnose and fatal if untreated.
There are two forms of disease: acute Rhodesian caused by Trypanosoma
brucei rhodesiense and chronic Gambian caused by T. b. gambiense.
In Uganda, there are 32 high-risk districts with Rhodesian sleeping
sickness threatening 9 million people, mostly in poor, rural areas. Nine
districts currently account for 80% of all reported Rhodesian sleeping
sickness cases in Uganda.
Uganda is unique in having both disease forms that were historically
widely separated. In 1999, the focus of the acute form began moving
towards the chronic disease focus threatening established, distinct
control measures. With > £10 million grants from DfID, Wellcome Trust,
and The European Commission Seventh Framework Programme, Prof Welburn
(Professor of Medical and Veterinary Molecular Epidemiology, University of
Edinburgh, employed 1999-present) provided the evidence base for a
new approach to control sleeping sickness in Uganda and established a
public-private partnership (PPP) (Stamp Out Sleeping Sickness. SoS) - a
unique One Health solution. A key collaborator has been The School of
Veterinary Medicine and Animal Resources, Makerere University, Kampala,
Uganda. Makerere veterinary school has been intimately involved in our
research on zoonotic disease for more than 20 years contributing
logistical and intellectual inputs.
Key underpinning research outputs:
-
Evidence that domestic cattle were the principal reservoir of human
infective Trypanosoma brucei rhodesiense in
Uganda (References 3.1-3.2)
For 100 years it was impossible to assess the risk posed by livestock
carrying both non-human-infective T. b. brucei and T. b.
rhodesiense that were indistinguishable. In 1999, we identified
and validated a robust molecular marker (sra) for human
infectivity in trypanosomes and UoE work revealed that up to 40% of
cattle in SE Uganda carried T. b. rhodesiense.
-
Evidence to support a new approach to sleeping sickness control, by
targeting the animal reservoir (References 3.1-3.3)
In 2001 our studies showed that outbreaks of sleeping sickness were
caused by importation of cattle from endemic areas. Using mathematical
modelling, we predicted that treating >86% of cattle would control
the spread of disease. We tested the model in Uganda by (i) mass
chemoprophylaxis of cattle to remove the parasites from the reservoir
hosts and (ii) application of insecticide to cattle to prevent
reinfection by tsetse. We showed that a single round of treatment could
eliminate human trypanosomes in the cattle reservoir and that a monthly
application of insecticide to cattle prevented reinfection.
References to the research
3.1 Welburn, S.C, Picozzi, K., Fevre, E.M., Coleman, P.G., Odiit, M.,
Carrington, M. and I. Maudlin (2001). Identification of human infective
trypanosomes in animal reservoir of sleeping sickness in Uganda by means
of serum-resistance-associated (SRA) gene. Lancet 358: 2017-19.
http://dx.doi.org/10.1016/S0140-6736(01)07096-9
3.2 Fevre, E.M. Coleman, P.G., Odiit, M.D., Magona, J., Welburn, S.C.,
and M.E.J. Woolhouse (2001). The origins of a new sleeping sickness
outbreak (caused by Trypanosoma brucei infection) in eastern
Uganda. Lancet 358: 625-628. http://dx.doi.org/10.1016/S0140-6736(01)05778-6
3.3 Fèvre, E.M., Picozzi, K., Fyfe, J., Waiswa, C., Odiit, M., Coleman,
P.G. and S.C. Welburn (2005). A burgeoning epidemic of sleeping sickness
in Uganda. Lancet 366: 747-747.
http://dx.doi.org/10.1016/S0140-6736(05)67179-6
Details of the impact
Impact on Health and Welfare:
Based on our research findings, in 2006 we established a
Public-Private-Partnership (PPP (University of Edinburgh, CEVA Sante
Animale (a global veterinary health company), IKARE (a UK-based charity) -
and the Government of Uganda) called Stamp Out Sleeping Sickness.
This was created to ensure:
(i) Mass treatment of cattle in five districts in the disease-overlap
zone
(ii) Compliance with Govt. policy to treat cattle at markets (a legal
obligation for the buyer, but not applied in practice)
(iii) The establishment of veterinary businesses to deliver a
cattle-spraying service and vet provision (where none was available in the
post-privatised system)
(iv) To tie in with Ministry of Health screening activities to coordinate
human and animal treatments.
We tested the interventions in seven districts of Uganda, targeting
500,000 cattle in two phases. In phase I, 250,000 cattle were treated and
in 2008, phase II, a further 150,000 cattle were treated. The clear
impact of intervention was the finding that a 75% reduction in total
trypanosome prevalence was achieved by mass treatment alone and sleeping
sickness cases have fallen year on year since the PPP was established
(it has been calculated that reported human cases have been reduced by
90%)[5.1]
To ensure the prevalence of the human infective parasite remains at a low
level, 15-20% of the at-risk cattle population need to be treated monthly
[5.2, 5.3, 5.6]. We are now involved with SoS in a three-year mass cattle
treatment programme - injection and spraying- to quickly reduce human
infective parasite prevalence in cattle [5.4; 5.9].
Impact on public policy
The model for sleeping sickness control we have developed is now promoted
by WHO and donor agencies. [5.2; 5.6; 5.7; 5.8]. To eliminate sleeping
sickness from SE Uganda a new approach to funding was needed to avoid the
pitfalls associated with public goods (sustainability and accountability).
Working with Social Finance (http://www.socialfinanceus.org)
we have developed a novel partnership to leverage private investment to
pay for sleeping sickness control by shifting donor funding towards
results based funding mechanisms (Development Impact Bonds) [5.9].
Impact on the economy
Human and animal health gains, as a result of reduced parasite
prevalence, have been independently quantified in terms of: sleeping
sickness cases averted; disability-adjusted life year (DALYs) averted
(with $ value) and care costs averted. Animal productivity gains as a
result of reduced parasite prevalence can be quantified in terms of
sleeping sickness parasite free cattle and Tick-free cattle - cattle
treatment also controls tick-borne diseases providing additional economic
impact. The economic benefit is estimated as $100-400M in human health
care costs plus an estimated $25 per head of cattle per year increased
productivity from improved animal health care provision in the poorest
communities (in post conflict districts of Uganda). [5.3; 5.5, 5.10,
5.11].
Sources to corroborate the impact
5.1. Christine Amongi PhD Thesis: Molecular Epidemiology Of Rhodesian
And Gambian Human African Trypanosomiasis In Kaberamaido District,
Uganda (University of Edinburgh). (Document available on request.)
5.2. Welburn S.C., Coleman, P.G., Fevre, E.M., Odiit, M., Maudlin, I and
M.C. Eisler (2006). Crisis, what crisis? Control of Rhodesian sleeping
sickness. Trends in Parasitology 22: 123-8. http://dx.doi.org/10.1016/j.pt.2006.01.011
5.3. Fèvre EM, Wissmann BV, Welburn SC, Lutumba P (2008) The burden of
human African trypanosomiasis. PLoS Neglected Tropical Diseases 2:e333.
http://dx.doi.org/10.1371/journal.pntd.0000333
5.4. World Health Organisation (2012): `Accelerating work to overcome the
global impact of neglected tropical diseases - A roadmap for
implementation'. Specific reference to the elimination of zoonotic
sleeping sickness in East Africa, WHO recommends targeting interventions
at the intermediate hosts (cattle) citing the DFID-RNSS research findings
as evidence supporting this strategy. http://tinyurl.com/ptqj7k6
5.5. Shaw, APM et al., (2013), Estimating the costs of tsetse control
options: An example for Uganda. Preventive Veterinary Medicine 110 (2013)
290- 303. Shows economic benefit of $100- 400 million in human health care
costs - plus an estimated 25$ per head of cattle per year in increased
productivity from improved animal health care provision in post conflict
districts of Uganda. http://dx.doi.org/10.1016/j.prevetmed.2012.12.014
5.6. Bardosh, K Charles Waiswa, C. and Welburn, S.C. (2013) Conflict of
interest: use of pyrethroids and amidines against tsetse and ticks in
zoonotic sleeping sickness endemic areas of Uganda. Parasites &
Vectors, 6:204. http://dx.doi.org/10.1186/1756-3305-6-204
5.7. The disease control model we have used in Uganda was developed with
Prof Hargrove (University of Stellenbosc) and simulates the effect of
interventions in terms of changes in parasite prevalence in cattle,
reduction in human health burden and improvement in animal health
(expressed as $). (Hargrove et al (2012) Modeling the control of
trypanosomiasis using Trypanocides or insecticide-treated livestock. PLoS
Neglected Tropical Diseases, 6 (5). E1615. http://dx.doi.org/10.1371/journal.pntd.0001615).
5.8. 2012 - SOS - One Health approach for securing health and livelihoods
in developing countries Risk Forum One Health Summit 2012, One Health:
Public health and livelihoods Control of "Neglected" Zoonoses: 19th - 23rd
February Davos. http://tinyurl.com/o4ag4fr
5.9. Zoonotic HAT targeted for elimination using SOS Model. Report of the
Interagency meeting on planning the prevention and control of neglected
zoonoses diseases, WHO, Geneva 5 -6 July 2011. http://tinyurl.com/ox6hp7l
In 2011, the WHO Strategic and Technical Advisory Group for Neglected
Tropical Diseases and partners adopted a roadmap for control, elimination
and eradication. The roadmap sets targets for the period 2012-2020. WHO
believes that despite the complexity of neglected tropical diseases, the
targets are achievable.
Organized by the Department of Neglected Tropical Diseases (NTD) of the
World Health Organization (WHO) with UNICEF/UNDP/World Bank/WHO Special
Programme for Research and Training in Tropical Diseases (TDR), the Food
and Agriculture Organization of the United Nations (FAO) and the Word
Animal Health Organization (OIE). http://tinyurl.com/or5u635
5.10. SoS Featured at three WHO/EU/DfID policy meetings on Neglected
Zoonoses. Flagship NZ project at the 3rd Neglected Zoonoses Conference
November 2010. Report of the NZD3 conference http://tinyurl.com/qfa3pyk
5.11. Center for Global Development and Social Finance June 2013.
Development Impact Bond Working Group Report. An Investment Strategy in
the Human Interest:
http://tinyurl.com/ou62qzq